Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belantamab mafodotin + dostarlimab
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Belantamab mafodotin + dostarlimab is an investigational combination therapy composed of two antibodies: belantamab mafodotin, an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) conjugated to a microtubule inhibitor (monomethyl auristatin F, MMAF), and dostarlimab, a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1)[1][3][9]. Belantamab mafodotin kills myeloma cells via antibody-dependent cellular cytotoxicity and direct microtubule disruption, while dostarlimab relieves immune suppression by blocking PD-1 interactions with its ligands (PD-L1/PD-L2), enhancing T-cell activity against cancer[6][8]. This combination is being investigated, primarily in relapsed/refractory multiple myeloma, for improved anti-tumor efficacy over monotherapy[1][3].
- Other names
- belamaf + dostarlimabbelantamab mafodotin-blmf + dostarlimab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)BCMA (B-cell maturation antigen)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on belantamab mafodotin + dostarlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belantamab mafodotin + dostarlimab.